This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody & ADC Summit At ChinaBio
Shanghai, China
Kerry Hotel Pudong, Shanghai, ChinaApril 28–29, 2026

Filippo Mulinacci, PhD
Chief Business Officer at Araris Biotech
Speaker

Profile

Dr. Filippo Mulinacci currently serves as Chief Business Officer at Araris Biotech AG, a cutting-edge biotech company pioneering novel antibody-drug conjugate (ADC) linker technology.

He holds a Master’s degree in Chemistry from Università degli Studi di Torino, a Ph.D. in Pharmaceutical Sciences from University of Geneva, and an MBA in General Management from University of St. Gallen.

With over two decades of experience across both scientific research and business development, Filippo began his career in pharmaceutical research at Serono SA, then transitioned into licensing and business development — taking on roles at F. Hoffmann-La Roche AG, Philogen S.p.A., and Basilea Pharmaceutica.

At Araris Biotech, he leads global business development, strategic partnerships, licensing, and alliance management, helping to bring next-generation oncology therapeutics toward clinical application.

Agenda Sessions

  • Highly Efficacious and Tolerated Multi-payload ADCs Assembled in One step without Any Antibody Engineering

    16:15